Blood
Articles in this Issue
How I manage major hemorrhage
Abstract Acute hemorrhage can be a life-threatening emergency that is complex in its management and affects many patient populations. The past 15 years has seen the introduction of c...
How I manage pregnant patients who are alloimmunized to RBC antigens
Abstract Hemolytic disease of the fetus and newborn (HDFN) remains an important cause of perinatal morbidity and mortality. HDFN is caused by maternal alloimmunization to red blood c...
FLT3 is genetically essential for ITD-mutated leukemic stem cells but dispensable for human hematopoietic stem cells
Abstract Leukemic stem cells (LSCs) fuel acute myeloid leukemia (AML) growth and relapse, but therapies tailored toward eradicating LSCs without harming normal hematopoietic stem c...
Sustained MRD negativity drives maintenance stop
Introduction to a How I Treat series on transfusion medicine
Transfusions are part of standard care in many areas across medicine and are the “bread and butter” of practice for many hematologists, yet high-quality evidence is lacking in many areas. Consequently...
Therapeutic switch from plasma to recombinant ADAMTS13 for patients with congenital TTP from Japanese real-world data
Abstract Congenital thrombotic thrombocytopenic purpura (cTTP) is an ultrarare disorder characterized by thrombocytopenia, microangiopathic hemolytic anemia, and ischemic organ damag...
How I treat patients who are refractory to platelet transfusions
Abstract Patients with thrombocytopenia requiring ongoing platelet transfusion support may develop inadequate platelet count increments, referred to as platelet refractoriness (PR),...
How I diagnose and treat cardiorespiratory complications of transfusion
Abstract Cardiorespiratory complications after blood transfusion are the leading cause of transfusion-related morbidity and mortality worldwide. Transfusion-related acute lung injury...
Adult T-cell leukemia/lymphoma coexistent with immune dysregulation–associated EBV+ lymphoproliferative disorder
IAP dependency of T-cell prolymphocytic leukemia identified by high-throughput drug screening
Abstract T-cell prolymphocytic leukemia (T-PLL) is an aggressive lymphoid malignancy with limited treatment options. To discover new treatment targets for T-PLL, we performed high-th...
How I treat challenging transfusion cases in sickle cell disease
Abstract Transfusion of red blood cells (RBCs) can be lifesaving for individuals living with sickle cell disease (SCD). However, alloimmunization after transfusion is more common wit...
rADAMTS13 in cTTP: a new standard of care?
Sustained bone marrow and imaging MRD negativity for 3 years drives discontinuation of maintenance post-ASCT in myeloma
Abstract Discontinuation of lenalidomide maintenance after autologous stem cell transplantation is a burning question within the multiple myeloma (MM) community, especially after the...
Expanding the universe of T-PLL targets
Prevention is better than cure
N-homocysteinylation of β-arrestins biases GPCR signaling and promotes platelet activation
Abstract Hyperhomocysteinemia (HHcy) is strongly associated with cardiovascular diseases (CVDs), and it has been identified as a risk factor for thrombotic diseases. Most patients wi...
Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT
Abstract Despite recent advances in graft-versus-host disease (GVHD) prophylaxis, novel approaches to effective prevention of chronic GVHD (cGVHD) remain of high importance. In this...
How I use noninvasive prenatal testing for red blood cell and platelet antigens
Abstract Alloimmunization during pregnancy occurs when a mother produces antibodies against fetal antigens, leading to complications like hemolytic disease of the fetus and newborn (...
Right time: stopping multiple myeloma maintenance
A new severe congenital neutropenia syndrome associated with autosomal recessive <i>COPZ1</i> mutations
Abstract We have identified a new inherited bone marrow failure syndrome with severe congenital neutropenia (CN) caused by autosomal recessive mutations in the coatomer protein compl...
CARs in pole position: ready for the race?
Trafficking on the road to neutropenia
Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study
ZUMA-12 is a multicenter phase 2 study evaluating axicabtagene ciloleucel (axi-cel) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy as part of first-line treatment for high-risk la...